NfL and EGFL7 as biomarkers for neuroaxoonal damage and BBB-integrity in neuroinflammation: a translational approach

B14

We hypothesize that marker for BBB-integrity (EGFL7) and neuroaxonal damage (NfL) resolve specific pathophysiologic aspects of Multiple Sclerosis (MS) pathology and that their combination helps to improve monitoring of pathological processes within the CNS and prognostic potential in patients with MS. Therefore we first of all plan to experimentally validate EGFL7 and NfL as markers for BBB-integrity and neuroaxonal damage by taking advantage of human and murine in vitro cultures under different conditions and experimental models of acute (focal inflammatory lesion, relapsing-remitting EAE, stroke) and chronic neuronal injury (chronic EAE models). In a second step we plan to unravel the influence of lesion localization within the CNS and their clearance routes from the CNS to the periphery (by modulating meningeal lymphatics, BBB-drainage and myeloid clearance function), on the peripheral marker levels. In a third step we plan to translate our findings to the patient using prospective multicenter cohorts (NationMS, Nalo-MS, Z02).

 

 

 

 

 

 

 

 

 

 

Principal Investigators:

Dr. med. Timo Uphaus
Klinik für Neurologie
Mainz
Timo.Uphaus@unimedizin-mainz.de

Univ.-Prof. Dr. med. Frauke Zipp
Klinik für Neurologie
Mainz
frauke.zipp@unimedizin-mainz.de

News

Thu, 15/09/2022
Photo gallery: Inflammation & Imaging Symposium in the MIC building
Muenster. From September 12th to 14th scientists from Muenster University and their international guests discussed the latest developments in research on inflammation and the imaging of the immune system at the 2nd Inflammation & Imaging Symposium. The annual event is jointly organised by several research networks from Münster, among them the CRC/TRR 128 “Multiple Sclerosis”. […]...more
Tue, 28/06/2022
CRC Retreat in Münster
Muenster. After a long pause, more than 90 participants of the CRC joined in Muenster Factory Hotel to update on the latest developments. We heard the most recent on a selection of the CRC projects and there was also plenty of time for fruitful discussion and socializing in the evening....more
Mon, 23/05/2022
EU Research Council awards Lydia Sorokin Advanced Grant
Münster – The biochemist and Principal investigator of the CRC 128 Prof. Dr. Lydia Sorokin has received the coveted “Advanced Grant” awarded by the European Research Council (ERC). The funding of ca. 2.3 million euros enables the realisation of outstanding research projects. Lydia Sorokin heads the Institute for Physiological Chemistry and Pathobiochemistry at Muenster University. […]...more